CDC awards $215 million as part of Cancer Moonshot initiative revival

Send a link to a friend  Share

[June 09, 2022]  (Reuters) - The U.S. Centers for Disease Control and Prevention (CDC) said it was awarding $215 million in first-year funding as part of reviving the erstwhile Obama administration's Cancer Moonshot initiative aimed at prevention and control of the disease.

The funding will be given to 86 recipients https://www.cdc.gov/
cancer/dcpc/about/foa-dp22-2202, including various U.S. states as well as indigenous tribes such as Cherokee Nation, Kaw Nation of Oklahoma and Navajo Nation, among others.

It is part of an overall five-year investment plan worth $1.1 billion into three national programs to prevent and control cancer, the CDC said https://www.cdc.gov/media/
releases/2022/p0608-cancer-award.html on Wednesday.

"This funding is a critical investment in support of President Biden's Cancer Moonshot initiative and our efforts to help ensure that everyone in the United States equitably benefits from the tools we have to detect and diagnose cancer," Health and Human Services Secretary Xavier Becerra said in the CDC statement.

[to top of second column]

U.S. Health and Human Services (HHS) Secretary Xavier Becerra delivers remarks during a visit with U.S. Vice President Kamala Harris to promote the Biden administration's infrastructure plans at the Northeast Bronx YMCA in the Bronx borough of New York City, New York, U.S., October 22, 2021. REUTERS/Mike Segar

U.S. President Joe Biden in February announced plans to reduce death rate from cancer by at least 50% over the next 25 years by speeding research and making more treatments available under the "Cancer Moonshot" initiative.

The initiative, launched in 2016, was led by Biden when he was vice-president.

(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)

[© 2022 Thomson Reuters. All rights reserved.]  This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.

Back to top